Search the Newsreel

J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30

J.P. Morgan has reiterated its Buy rating for Kalera Therapeutics (KLRA.US) and maintained its target price at $30. This suggests a continued positive outlook from the investment bank regarding the company's stock performance.

Top Kailera Therapeutics (KLRA) Competitors 2026

Form 8K Kailera Therapeutics For: 12 August By Investing.com

This article reports on a Form 8K filing by Kailera Therapeutics for August 12. It provides the financial news item along with market data and various unrelated news headlines and stock performance figures from Investing.com. The core content is very brief, mainly serving as …

KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings

KAILERA THERAPEUTICS ($KLRA) announced its Q2 2026 earnings, reporting a loss of -$1.09 per share, missing analyst estimates of -$0.77, and revenue of $0, meeting estimates. Following the announcement, the stock price decreased by 2.1%. The article also details recent insider trading activity, significant …

Kailera Therapeutics Submits Q2 2026 10-Q Highlighting Financial Status and Operational Risks

Kailera Therapeutics, a clinical-stage biotechnology firm, filed its Q2 2026 10-Q report, detailing its ongoing financial losses and lack of revenue since inception. The company emphasized its need for significant additional capital to continue operations and highlighted critical risks such as maintaining its Hengrui …

Kailera Therapeutics, Inc. 2Q 2026: Revenue N/A, Net loss $(111.3M), EPS $(1.09) — 10-Q Summary

Kailera Therapeutics, Inc. reported no revenue and a significantly widened net loss of $(111.3M) for Q2 2026, resulting in an EPS of $(1.09). Despite financial losses, the company highlighted progress in its GLP-1–based pipeline, including positive Phase 3 results for ribupatide and KAI-7535 from …

Kailera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Jiangsu Hengrui discloses 8.9% Kailera Therapeutics (KLRA) stake in ownership filing

Jiangsu Hengrui Pharmaceuticals Co., Ltd. has reported a beneficial ownership of 8.9% in Kailera Therapeutics, Inc., holding 11,511,853 shares of common stock. This stake includes shares held directly by Jiangsu Hengrui and one share through its wholly-owned subsidiary, Hengrui (USA) Ltd., with the company …

Kailera Therapeutics, Inc. Revenue Breakdown – NASDAQ:KLRA

This page provides a revenue breakdown for Kailera Therapeutics, Inc. (NASDAQ: KLRA) on TradingView. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment performance. Users can explore financial data by source and country, along with other fundamental and …

Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential

Kailera's oral GLP-1 pill posted 11.1% weight loss in Phase 3

Enterprise value to revenue forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA

Kailera Therapeutics IPO And Governance Shift Draw Investor Attention

Kailera Therapeutics, Inc. - KLRA - Stock Price Today

Kailera Therapeutics (KLRA) Stock Price, News & Analysis $KLRA